Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Liabilities and Shareholders Equity (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Liabilities and Shareholders Equity for 7 consecutive years, with $1.7 billion as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 78.2% to $1.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.9 billion through Dec 2025, up 32.02% year-over-year, with the annual reading at $1.7 billion for FY2025, 78.2% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $1.7 billion at Kymera Therapeutics, up from $1.1 billion in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $1.7 billion in Q4 2025, with the low at $434.4 million in Q2 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $770.0 million, with a median of $626.2 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity dropped 13.48% in 2023, then soared 87.34% in 2024.
  • Over 5 years, Liabilities and Shareholders Equity stood at $605.9 million in 2021, then decreased by 0.46% to $603.1 million in 2022, then dropped by 4.54% to $575.8 million in 2023, then surged by 69.87% to $978.0 million in 2024, then surged by 78.2% to $1.7 billion in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $1.7 billion, $1.1 billion, and $1.1 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.